Pramod Kumar Srivastava
Pramod Kumar Srivastava | |
|---|---|
| Born | August 15, 1955 India |
| Alma mater | University of Connecticut |
| Known for | Research on cancer vaccines and tumor immunology |
| Scientific career | |
| Fields | Immunology, Cancer immunotherapy |
| Institutions | University of Connecticut School of Medicine |
Pramod Kumar Srivastava (born 15 August 1955) is an American immunologist and physician. He serves as the Eversource Energy chairman in experimental oncology at the University of Connecticut School of Medicine. His research focuses on cancer vaccines.[1][2][3][4]
He is the scientific founder of Antigenics (AGEN), the New York-based biotech company.[2][3]
Early life and education
Srivastava completed his Ph.D. at the Centre for Cellular and Molecular Biology, Hyderabad, India, and his MD from the University of Connecticut School of Medicine.[2][4][5]
Career
In 1989, Srivastava was appointed Assistant Professor in the Department of Pharmacology at Mount Sinai School of Medicine. In 1993, he joined Fordham University as an Associate Professor of Biology and was promoted to full Professor in 1995. In 1994, he co-founded the biotechnology company Antigenics.[2][6]
In 1997, Srivastava joined the University of Connecticut School of Medicine as a Professor of Medicine. He later became the founding director of the Center for Immunotherapy of Cancer and Infectious Diseases.[5] and served as the founding chairman of the Department of Immunology. Since 2011, he has been the director of the Carole and Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine.[1][2][4]
Scientific and clinical work
Srivastava’s research has focused on neuroimmunology. His laboratory has studied the role of heat shock proteins in antigen presentation and immune activation. His work has also examined transient receptor potential vanilloid (TRPV) receptors on dendritic cells and their potential role in immune regulation in the gut.
In addition, his research has explored interactions between the nervous and immune systems, including the role of sympathetic nervous system signaling in neutrophil development and in the regulation of myeloid-derived suppressor cells and regulatory T cells.[1]
Publications
Srivastava has authored more than 200 peer-reviewed publications in cancer immunology and related fields. His work has appeared in journals including Science, Nature Immunology, Immunity, The Journal of Experimental Medicine, and PNAS.
Selected publications include studies on:
- Heat shock protein–mediated antigen presentation
- CD91 as a receptor for heat shock proteins
- Mechanisms of cross-priming in CD8+ T cells
- Genomic profiling of mutational neoepitopes
- Sympathetic nervous system regulation of myeloid-derived suppressor cells
- Immune regulation in the gut and neuroimmunology interactions
References
- ^ a b c "UConn Health tests its own biotech breakthroughs". Hartford Business Journal. 7 January 2019. Retrieved 2023-12-07.
- ^ a b c d e Courant, Hartford (2016-01-22). "Farmington Doctor Is Battling Cancer At Genetic Level". Hartford Courant. Retrieved 2023-12-07.
- ^ a b Street Journal, Laura JohannesStaff Reporter of The Wall (1999-11-18). "Tailor-Made Cancer Vaccines Show Promise in Early Trials". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-07.
- ^ a b c Knight, Jonathan (2001-02-24). "Your best shot". New Scientist. Retrieved 2023-12-07.
- ^ a b By (1998-02-17). "RESEARCHERS TURN TO HUMAN IMMUNE SYSTEM". Hartford Courant. Retrieved 2023-12-07.
- ^ Weiss, Rick (1996-02-27). "CANCER VACCINE". Washington Post. ISSN 0190-8286. Retrieved 2023-12-07.